Stockreport

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma, Inc.  (LYEL) 
PDF Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lym [Read more]